

# Elisabetta Maffioletti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9105316/publications.pdf>

Version: 2024-02-01

26  
papers

831  
citations

687363

13  
h-index

610901

24  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1684  
citing authors

#	ARTICLE	IF	CITATIONS
1	Blood microRNA changes in depressed patients during antidepressant treatment. <i>European Neuropsychopharmacology</i> , 2013, 23, 602-611.	0.7	197
2	Peripheral whole blood microRNA alterations in major depression and bipolar disorder. <i>Journal of Affective Disorders</i> , 2016, 200, 250-258.	4.1	138
3	Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 75.	3.7	100
4	miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 82, 102-109.	3.1	76
5	ROLE OF ALLELIC VARIANTS OF FK506-BINDING PROTEIN 51 (FKBP5) GENE IN THE DEVELOPMENT OF ANXIETY DISORDERS. <i>Depression and Anxiety</i> , 2013, 30, 1170-1176.	4.1	42
6	Insulin-like Growth Factor 1 Differentially Affects Lithium Sensitivity of Lymphoblastoid Cell Lines from Lithium Responder and Non-responder Bipolar Disorder Patients. <i>Journal of Molecular Neuroscience</i> , 2015, 56, 681-687.	2.3	35
7	Association between baseline serum vascular endothelial growth factor levels and response to electroconvulsive therapy. <i>Acta Psychiatrica Scandinavica</i> , 2014, 129, 461-466.	4.5	34
8	Influence of clotting duration on brain-derived neurotrophic factor (BDNF) dosage in serum. <i>BioTechniques</i> , 2014, 57, 111-114.	1.8	34
9	Biological correlates of early life stressful events in major depressive disorder. <i>Psychoneuroendocrinology</i> , 2021, 125, 105103.	2.7	23
10	BDNF Genotype and Baseline Serum Levels in Relation to Electroconvulsive Therapy Effectiveness in Treatment-Resistant Depressed Patients. <i>Journal of ECT</i> , 2019, 35, 189-194.	0.6	19
11	Blues in the Brain and Beyond: Molecular Bases of Major Depressive Disorder and Relative Pharmacological and Non-Pharmacological Treatments. <i>Genes</i> , 2020, 11, 1089.	2.4	17
12	miR-146a Plasma Levels Are Not Altered in Alzheimer's Disease but Correlate With Age and Illness Severity. <i>Frontiers in Aging Neuroscience</i> , 2020, 11, 366.	3.4	17
13	Inflammation-related microRNAs are involved in stressful life events exposure and in trauma-focused psychotherapy in treatment-resistant depressed patients. <i>Hogrefe Utbildning</i> , 2021, 12, 1987655.	3.0	16
14	Association study between <i>HTR2A</i> rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients. <i>Drug Development Research</i> , 2020, 81, 754-761.	2.9	15
15	Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response. <i>Drug Development Research</i> , 2020, 81, 593-599.	2.9	14
16	Study of the in vitro modulation exerted by the antidepressant drug escitalopram on the expression of candidate microRNAs and their target genes. <i>Molecular and Cellular Neurosciences</i> , 2017, 85, 220-225.	2.2	11
17	Molecular Biomarkers of Electroconvulsive Therapy Effects and Clinical Response: Understanding the Present to Shape the Future. <i>Brain Sciences</i> , 2021, 11, 1120.	2.3	11
18	Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2307-2312.	2.2	7

#	ARTICLE	IF	CITATIONS
19	Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review. <i>European Neuropsychopharmacology</i> , 2022, 55, 112-157.	0.7	7
20	Nanomedicine in Psychiatry: New Therapeutic Opportunities from Research on Small RNAs. <i>Drug Development Research</i> , 2016, 77, 453-457.	2.9	4
21	Recommendations for pharmacotranscriptomic profiling of drug response in CNS disorders. <i>European Neuropsychopharmacology</i> , 2022, 54, 41-53.	0.7	4
22	Effetti biomolecolari del maltrattamento infantile: il ruolo dell'epigenetica e dell'infiammazione. <i>Maltrattamento E Abuso All'Infanzia</i> , 2015, , 35-54.	0.5	3
23	Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA) <a href="#">Tj ETQq1 1 0.7843d 4 rgBT4Overlo</a>	1.0	0
24	Defining an immune signature predictive of glioma progression. <i>Journal of Neuroimmunology</i> , 2014, 275, 35.	2.3	0
25	F49GENETIC DETERMINANTS OF CIRCULATING VEGF LEVELS IN MAJOR DEPRESSIVE DISORDER. <i>European Neuropsychopharmacology</i> , 2019, 29, S1135-S1136.	0.7	0
26	P.264 Association of single nucleotide polymorphisms in the 3'UTR untranslated region of SLC1A2 with major depressive disorder and relative endophenotypes. <i>European Neuropsychopharmacology</i> , 2020, 40, S150-S151.	0.7	0